A bacterial assist for CAR-T cells

Cancer therapy with chimeric antigen receptor (CAR)-T cells has achieved impressive remissions in certain hematologic malignancies, and extending the approach to other types of cancer is a key goal of immunotherapy research. Solid tumors have proved particularly challenging because of immunosuppressive mechanisms in the tumor microenvironment. Writing in Science, Danino and colleagues outline a new strategy for deploying CAR-T cells against solid tumors: use engineered bacteria to coat the interior of the tumor with a synthetic antigen and then treat with CAR-T cells specific for the synthetic antigen.

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

24,99 € / 30 days

cancel any time

Subscribe to this journal

Receive 12 print issues and online access

209,00 € per year

only 17,42 € per issue

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Log in

Learn about institutional subscriptions

Read our FAQs

Contact customer support

About this article

Cite this article

Aschheim, K. A bacterial assist for CAR-T cells.
Nat Biotechnol 41, 1521 (2023). https://doi.org/10.1038/s41587-023-02042-w

Download citation

Published: 10 November 2023

Issue Date: November 2023

DOI: https://doi.org/10.1038/s41587-023-02042-w

>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : Nature.com – https://www.nature.com/articles/s41587-023-02042-w